Abstract: Pulmonary arterial hypertension (PAH) is a fatal disease, and the ultimate cause of death is right ventricular (RV) failure. In this study, we investigated the acute hemodynamic effects of levosimendan in two rat models of RV hypertrophy and failure. Wistar rats were randomized to receive sham surgery (n ¼ 8), pulmonary trunk banding (PTB; n ¼ 8), or monocrotaline injection (MCT; n ¼ 7). RV function was evaluated at baseline and after injection of placebo and two concentrations of levosimendan (12 and 60 μg/kg) using magnetic resonance imaging, echocardiography, and invasive pressure recordings. PTB and MCT injection caused hypertrophy, dilatation, and failure of the RV compared with sham surgery. Levosimendan increased RV end systolic pressure (sham surgery: 16.0% AE 3.8% [P ¼ 0.0038]; MCT: 9.9% AE 3.1% [P ¼ 0.018]; PTB: 24.5% AE 3.3% [P ¼ 0.0001]; mean AE SEM) compared with placebo. Levosimendan markedly increased RV stroke volume (SV) in the MCT group (29.1% AE 8.3%; P ¼ 0.012), did not change RV SV in the PTB group (0.4% AE 4.5%; P ¼ 0.93), and decreased RV SV in the sham surgery group (−10.9% AE 3.7%; P ¼ 0.020). Nitroprusside, which was used to mimic the systemic arterial vasodilator action of levosimendan, did not influence RV function. These data demonstrate that levosimendan acutely improves the failing right heart in a MCT model of PAH and that the mechanism involves a direct acute positive inotropic effect on the hypertrophic and failing RV of the rat.
INTRODUCTION
Pulmonary arterial hypertension (PAH) is characterized by constriction or partial obstruction of the pulmonary vasculature, causing increased afterload and eventually right ventricular (RV) failure and death. Despite modern medical management, 3-year survival is only slightly better than 50%. 1 RV function is the most decisive factor of longevity in patients with PAH. 2 Under normal conditions, the RV works in a low-pressure system and adapts easily to minor changes in afterload. But with increased afterload in PAH, the RV undergoes hypertrophy and dilatation. This commences a vicious cycle with lowered cardiac output (CO), insufficiency of the tricuspid valve, and myocardial hypoperfusion as the disease progresses. [3] [4] [5] Levosimendan is a calcium-sensitizing agent that increases contractility in cardiomyocytes without increasing intracellular calcium concentrations and oxygen demand. 6, 7 This makes levosimendan an optimal treatment strategy in a failing and hypoperfused ventricle. Levosimendan also dilates systemic and pulmonary blood vessels, possibly by opening of adenosine triphosphate-dependent potassium channels. 8, 9 Levosimendan is used in patients with acute left ventricular failure. But the hemodynamic profile of the drug might also be beneficial in the acute settings of the failing RV. In a few previous animal studies, levosimendan acutely improved the function of a failing RV directly or through afterload reduction. [10] [11] [12] [13] [14] Data on levosimendan in patients with PAH are very sparse and conflicting. [15] [16] [17] [18] The aim of this study was to investigate the effects of levosimendan in a rat pulmonary trunk banding (PTB) model of RV hypertrophy and failure and in a monocrotaline (MCT) rat model of PAH. Use of the rat PTB model allows estima-tion of the direct RV myocardial effects of levosimendan independently of the pulmonary vasodilator action of this drug. In addition, the effects of nitroprusside were investigated in both models of RV failure to mimic the systemic arterial vasodilator effect of levosimendan.
METHODS

Study design
Male Wistar rats were randomized to receive PTB (n ¼ 8), sham surgery (n ¼ 8), or MCT injection (n ¼ 7). Evaluation was performed 28 days after PTB/sham surgery and 21 days after MCT injection when RV failure was present. A repeated-measurement design was performed for each rat regardless of randomization group: baseline measurement was followed by measurements after placebo (isotonic saline) injection and after two doses of levosimendan: Levo-12 (loading dose of 12 μg/kg followed by infusion of 0.1 μg/kg/min in 10 minutes) 19 and Levo-60 (loading dose of 60 μg/kg followed by infusion of 0.5 μg/kg/min in 10 minutes; Fig. 1 ). This was repeated on two consecutive days in all animals, where magnetic resonance imaging (MRI) was performed on day 1 and echocardiography and invasive pressures were performed on day 2 ( Fig. 1 ).
Drug administration
Placebo and levosimendan (Simdax; Orion, Espoo, Finland) were given at the smallest possible and equal volumes through a Venflon intravenous catheter dipped in heparin to avoid thrombosis. Levosimendan was diluted in saline prior to the experiments. The effects of levosimendan peak after about 10 minutes, 6 and we aimed to evaluate the immediate acute effects. Doses were chosen as a clinically relevant dose (Levo-12) and a dose that was five times higher (Levo-60). preset to an inner diameter of 0.5 mm was placed around the pulmonary trunk. The rats received 2 mL of isotonic saline and 0.10 mg/kg buprenorphine (Anorfin; GEA, Frederiksberg, Denmark) subcutaneously to prevent fluid loss and pain, respectively. Buprenorphine was added to the drinking water (7.4 μg/mL) for 3 days after the procedure to relieve postoperative pain. Rats undergoing sham Figure 1 . Study design. Rats were evaluated when right ventricular (RV) failure was present 28 days after pulmonary trunk banding (PTB)/sham surgery and 21 days after monocrotaline (MCT) injection. The evaluation protocol for each rat was magnetic resonance imaging (MRI) on day 1 and echocardiography (ECHO) and invasive pressure measurement (IPM) on day 2. TAPSE: tricuspid annular plane systolic excursion.
surgery were treated the exact same way except for the placement of the titanium clip.
MCT MCT (Crotaline; Sigma-Aldrich, St. Louis, MO) was dissolved in 6 M HCl, adjusted to pH 7.4 with 10 M NaOH, diluted in saline, and given intraperitoneally in a dose of 60 mg/kg while the rats were anesthetized. MCT treatment was initiated 1 week after PTB to ensure matching age groups and degree of disease on the day of evaluation. Inclusion criteria for both PTB and MCT was that the rats survived the evaluation procedure and had a tricuspid annular plane systolic excursion (TAPSE) value of <0.16 mm. 22 
Nitroprusside
To investigate whether the RV effects of levosimendan could be secondary to systemic arterial vasodilation, another group of rats were randomized to receive PTB (n ¼ 6), MCT injection (n ¼ 6), or sham surgery (n ¼ 6). After 28 days (PTB/sham surgery) or 21 days (MCT), all rats were evaluated with invasive pressures. After baseline and placebo (saline) measurement, sodium nitroprusside (Nitropress; Hospira, Lake Forest, IL) at 50 μg/mL (diluted in 5% glucose) 23 was infused. Beginning with an infusion speed of 0.1 mL/h, the dose was increased by 0.1 mL/h every second minute until a reduction in mean arterial pressure (MAP) comparable to that achieved by levosimendan injection was reached.
MRI scanning A 1.5-T whole-body MRI scanner (Magnetom Avanto; Siemens, Erlangen, Germany) was used. The rats were anesthetized with 3% sevoflurane, placed in a four-element wrist coil, and kept with spontaneous respiration during the scan. The electrocardiogram signal and respiration was recorded to trigger scanning between expiration and inspiration (SAII; Stony Brook, NY). A stack of six contiguous slices encompassing the heart from base to apex in the cardiac short-axis orientation was acquired. We used a prospectively triggered spoiled gradient echo cine sequence.
The imaging parameters were as follows: repetition time (TR) ¼ 9.26 ms, echo time (TE) ¼ 3.96 ms, flip angle ¼ 15°, acquisition matrix ¼ 128 Â 128, field of view ¼ 60 mm Â 60 mm, spatial in-plane resolution ¼ 0.47 mm Â 0.47 mm, slice thickness ¼ 2 mm, and number of heart phases ¼ 21. Data were evaluated using Segment (http://segment .heiberg.se) cardiac analysis software.
Stroke volume (SV) was measured in the pulmonary artery using a phase contrast sequence. The measurement position was centred after the pulmonary valves and in the PTB group before the clip. The sequence parameters were as follows: TR ¼ 12. To increase temporal resolution, all flow measurements were repeated twice, with the second delayed by 6 ms relative to the first. This is reasonable because the data readout was finished after 6 ms, while the remaining TR time was "dead time." The two data sets were combined and flow values obtained using specific analysis software (Siswin). All data evaluation was performed with the observer blinded to the sample source.
Echocardiography and catheter measurements
Rats were anesthetized and ventilated as described above. A 1.4-F Millar pressure tip catheter (Millar Instruments, Houston, TX) was calibrated and inserted through the right jugular vein into the RV. 24 RV systolic and diastolic pressure, RV dP/dt max , and RV dP/dt min was recorded using NOTOCORD (NOTOCORD Systems SAS, Midland, NC). A similar catheter was inserted into the left carotid artery to measure systemic blood pressure (BP). Pulmonary vascular resistance-that is, RV afterload-was estimated as RV systolic pressure divided by RV CO. 25 Echocardiography (Vivid 7; GE Healthcare, Wauwatosa, WI) was performed with an 11-MHz phased array pediatric transducer with a frame rate of about 150 Hz. 22 We recorded tricuspid regurgitation and TAPSE. Analysis of the images was performed offline using EchoPAC software (GE Healthcare), with the observer blinded to the source of the samples. Three consecutive heart cycles were analyzed for each individual rat, and the mean was used as a representative value.
Anatomical measurements
Rats were euthanized by drain of blood. We weighed the RV, liver, spleen, and lungs (Sartorius, Göttingen, Germany) and measured the length of the tibia. RVs were preserved in 4% formaldehyde (pH 7) histology. Blood was centrifuged, and the plasma was kept at −20°C.
Histology and enzyme-linked immunosorbent assay (ELISA) RV tissue was handled as previously described. 26 We calculated a mean fibrosis value from three randomly chosen images of each RV. The concentration of atrial natriuretic peptide (ANP) was measured using a commercial ELISA kit (E90225Ra, USCN Life Science, Wuhan, Hubei, China) in accordance with the manufacturer's protocol. Absorbance was read at 450 nm (PHERAstar FS; BMG Labtech, Ortenberg, Germany).
Statistical analysis
All values are mean AE SEM. A one-way analysis of variance (ANOVA) for repeated measurements was performed. If significant, paired t tests between relevant groups were calculated. No post hoc multicomparison test was performed for easier interpretation of the results by the reader, as suggested by Saville. 27 We used GraphPad Prism (ver. 5.0;
GraphPad Software, San Diego, CA) as statistical software. Differences between groups were tested with unpaired t tests. If data were not normally distributed, equivalent nonparametric tests were performed. P < 0.05 was considered significant.
RESULTS
Effects of PTB and MCT on RV hypertrophy and failure As seen in Table 1 and Figure 2 , there was an increase in RV weight/tibia length in the PTB and MCT groups compared with the sham surgery group. Furthermore, the lungs of the MCT rats were heavier, whereas the PTB rat RVs had more fibrosis. At baseline, the PTB and MCT rats had increased end systolic volume, lower CO, and lower TAPSE compared with the sham surgery rats (Table 2) . Heart rate (HR), SV, and ejection fraction were lower compared with the sham surgery rats. The RVs in the PTB and MCT groups showed increased RV end systolic pressure (RVsP) and estimated pulmonary vascular resistance compared with RVs in the sham surgery group. Tricuspid insufficiency was present in all PTB and MCT rats, unlike in the sham surgery rats. Additionally, the PTB group was further hypertrophied and had even higher RVsP and dP/dt max than the MCT group, whereas the MCT rats had lower RV SV, CO, and systemic BP than the PTB rats.
Acute hemodynamic effects of levosimendan
As seen in Figure 3 , both RVsP and RV contractility measured by dP/dt max increased compared with placebo in all groups after levosimendan infusion. Similarly, dP/dt min improved in all groups with levosimendan injection compared with placebo injection. HR was increased only in the PTB group after Levo-60 infusion compared with placebo (7.4% AE 3.1%; P ¼ 0.047).
Using MRI, we found that RV SV increased in the MCT group. No RV SV changes were recorded in the PTB group, and a decrease was found in the sham surgery rats.
No changes were recorded between baseline and placebo except for a decline in RV dP/dt max and dP/dt min in the PTB group and in mean systemic BP in the PTB and sham surgery groups. Infusion of Levo-60 reduced mean systemic BP in all groups (Fig. 4) .
Nitroprusside
With nitroprusside, we obtained a decrease in MAP comparable to the reduction in MAP seen when infusing Levo- 12 and Levo-60. At these levels, there were no changes in RV dP/dt max in any of the three groups (Fig. 4) .
DISCUSSION
In this study, we demonstrate that levosimendan acutely improves the failing RV in the MCT rat model of PAH. Levosimendan also improves the failing RV in a PTB model, demonstrating a direct RV inotropic action of this drug. Nitroprusside did not influence RV function in the two animal models of RV failure, indicating that the observed effects of levosimendan on RV function was not related to the arterial vasodilator component of this drug.
Effects of PTB and MCT on RV hypertrophy and failure Our models of PTB and MCT efficiently caused RV hypertrophy and failure compared with sham surgery. The MCT administration caused an increase in RV weight, lung weight, and RV dP/dt max , in accordance with previous studies, 28, 29 and an RVsP comparable to that in rats injected with an even higher MCT dose. 29 PTB caused hypertrophy and pathologic remodeling, evident by the increase in RV weight normalized for tibia length and increased fibrosis fractional area. 26 Failure of the RV was evident by a decrease in CO, an increase in EDV, and tricuspid regurgitation compared with sham surgery. In both models of RV failure, the body weight of the rats was lower than that of sham surgery rats at euthanasia, which indicates a general level of dysfunction, as seen by others 30, 31 (Table 1) . Adjusted for tibia length, RV weights in both RV failure models increased to more than double to overcome the increased RV afterload compared with sham surgery. It was, however, only in the PTB group that fibrosis increased significantly. With the same inclusion criteria based on an equally lower TAPSE, the MCT model showed more signs of RV failure, including increased ANP levels in the blood. These observations made us confident that the models were suitable to evaluate the effects of levosimendan in the failing hypertrophic right heart. Effects of levosimendan on right heart hypertrophy and failure Administration of levosimendan caused an increase in RV end systolic pressure and dP/dt max with increasing levosimendan concentrations in sham surgery, MCT, and PTB animals. This finding is in accordance with previous studies in nondilated, hypertrophic RVs 32, 33 and reveals a contractile reserve even in a dilated, hypertrophied, and failing RV. Compared with placebo, mean arterial BP decreased with increasing concentrations of levosimendan, which confirms a similar systemic vasodilatory effect of levosimendan in all groups (although nonsignificant in the MCT group), as described previously in healthy rats. 20 We found no changes in RV dP/dt max or other functional parameters at equivalent levels of BP reduction caused by nitroprusside (Fig. 4) . This supports that the improved RV contractility is not caused or modified by systemic arterial vasodilation.
It was only in the MCT group that the RV managed to transform the increased contractility and pressure into a raised SV. Levosimendan has a well-described pulmonary vasodilatory effect, 34 which likely explains the additional improvement compared with PTB animals with a fixed afterload. In the PTB rats, levosimendan was unable to decrease RV afterload due to the fixed constriction, and hence the RV SV was unchanged. In the sham surgery group there was a decrease in RV SV. This might be due to failure of levosimendan to further dilate the healthy pulmonary vascular tree, as described by others, 14 combined with a systemic arterial vasodilatory action, peripheral pooling, and a reduction in preload. In the MCT and PTB groups, we would expect central venous pressure to be sufficiently high to maintain RV filling pressure despite peripheral pooling. Increasing levosimendan doses also improved RV lusitropy measured by RV dP/dt min in all three groups. This has been described in isolated septic guinea pig hearts but not in septic isolated rat hearts. 35, 36 The calcium-sensitizing effect of levosimendan is dependent on calcium concentration, 6,37 explaining a decreased effect in diastole and hence an improved lusitropic state. Our results reveal that this positive lusitropic action also applies in a hypertrophied failing RV. We barely observed changes in HR. This indicates that our observed changes in SV are of greater importance than changes in HR in order to increase CO, which also has been suggested in humans. 9 Levosimendan increases HR in humans, 9 but we and others find only small or no changes in HR in rats, implying a species-dependent chronotropic effect of levosimendan. 14, 35 In conclusion, we have demonstrated that levosimendan acutely improves the failing RV in a MCT model of PAH and that this beneficial profile involves a direct acute positive inotropic and lusitropic effect on the myocardium of the RV of the rat.
Limitations
All experiments were performed on Wistar Galas outbred rats. This should be taken into consideration, and further in vivo studies in other animal models are warranted before translating our findings to the clinical setting, as suggested by Lawrie. Figure 3b . Two asterisks indicate P < 0.01 versus placebo, three asterisks indicate P < 0.001 versus placebo, one pound sign indicates P < 0.05 versus Levo-12, and three pound signs indicate P < 0.001 versus Levo-12. Data are mean AE SEM. PTB: pulmonary trunk banding; MCT: monocrotaline.
